Company Monitoring Page for Clovis-Oncology

latest headlines for company on cafepharma

Rubraca sheds positive light for PARP inhibitors in endometrial cancer
Clinical Trials Arena
Tue, 04/2/24 - 11:43 am
Tags:
Rubraca, Clovis Oncology, endometrial cancer, clinial trials
FDA rejects Clovis' long-shot bid for approval of Rubraca
Fierce Pharma
Mon, 06/5/23 - 11:29 am
Tags:
Clovis Oncology, Rubraca, FDA, bankruptcy
Clovis sells off remaining assets—including cancer drug Rubraca—for $70M-plus
Fierce Pharma
Mon, 04/10/23 - 11:28 am
Tags:
Clovis Oncology, Rubraca, bankruptcy, Pharma & Schweiz
Amid bankruptcy, Clovis reveals more regulatory troubles for Rubraca
Fierce Pharma
Mon, 02/13/23 - 10:48 am
Tags:
Clovis Oncology, Rubraca, ovarian cancer, bankruptcy
Clovis files for bankruptcy, will keep operating and plans to sell pipeline asset to Novartis
Endpoints
Mon, 12/12/22 - 10:14 am
Tags:
Clovis Oncology, bankruptcy, Novartis
In free fall, Clovis defaults on loan and agrees to further restrict Rubraca use
Fierce Pharma
Mon, 12/5/22 - 11:07 am
Tags:
Clovis Oncology, Rubraca, FDA, ovarian cancer
With the walls closing in for Clovis, FDA demands ovarian cancer restriction for Rubraca
Fierce Biotech
Thu, 11/17/22 - 10:52 am
Tags:
Clovis Oncology, Rubraca, ovarian cancer, FDA
Clovis Oncology flags possible bankruptcy in 'very near term'
NASDAQ
Wed, 11/9/22 - 10:47 am
Tags:
Clovis Oncology, bankruptcy, Rubraca
As Rubraca faces questions in ovarian cancer, Clovis trots out a prostate cancer partial win
Fierce Pharma
Mon, 10/3/22 - 11:30 pm
Tags:
Clovis Oncology, Rubraca, ovarian cancer, prostate cancer
ESMO 2022 movers – KRAS backfires
EP Vantage
Thu, 09/15/22 - 10:12 am
Tags:
ESMO, KRAS inhibitors, Relay Therapeutics, Regeneron, Amgen, Deciphera, Clovis Oncology, Ayala Pharmaceuticals, Springworks, Mirati Therapeutics
Undeterred by FDA warning, desperate Clovis seeks Rubraca nod in front-line ovarian cancer
Fierce Pharma
Wed, 09/14/22 - 09:47 am
Tags:
Clovis Oncology, Rubraca, FDA, ovarian cancer
Clovis, in need of cash or deals now to stem looming financial challenges, looks to pipeline for ideas
Fierce Biotech
Tue, 08/9/22 - 06:29 am
Tags:
Clovis Oncology, Rubraca, ovarian cancer, funding
Why Clovis Oncology Stock Went Into Retreat Mode This Week
Motley Fool
Fri, 07/15/22 - 10:39 am
Tags:
Clovis Oncology, Rubraca
Why Clovis Oncology Stock Was Blasting Off Tuesday
Motley Fool
Tue, 06/21/22 - 11:43 pm
Tags:
Clovis Oncology, clinical trials, FAP-2286, solid tumors
Clovis quietly unveils crippling FDA delay as its troubles deepen
Fierce Pharma
Fri, 05/6/22 - 11:05 am
Tags:
Clovis Oncology, FDA, Rubraca, ovarian cancer
Clovis equity investors overlook two elephants
EP Vantage
Fri, 04/1/22 - 10:27 am
Tags:
Clovis Oncology, Rubraca, ovarian cancer
Corcept, Clovis Score Wins in Advanced Ovarian Cancer
BioSpace
Thu, 03/31/22 - 10:32 am
Tags:
Clovis Oncology, Corcept Therapeutics, ovarian cancer, clinical trials
Clovis Oncology, Evergreen partner for actinium-225-labeled FAP-2286
Pharmaceutical Business Review
Thu, 03/17/22 - 10:16 am
Tags:
Clovis Oncology, Evergreen Theragnostics, radiolabeling
ASCO-GU – prostate cancer PARPS move to the front line
EP Vantage
Sun, 02/20/22 - 11:44 am
Tags:
prostate cancer, ASCO-GU, PARP inhibitors, Lynparza, Zejula, Rubraca, Talzenna, biomarkers, AstraZeneca, Merck, GSK, JNJ, Clovis Oncology
Why Clovis Oncology Shares Got a Bump This Week
Motley Fool
Sat, 08/28/21 - 08:55 pm
Tags:
Clovis Oncology, earnings, Rubraca

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.